1.Clinical efficacy of immunotherapy plus targeted therapy combined with local treatment for unresectable hepatocellular carcinoma
Weichen ZHANG ; Songfeng YU ; Tanyang ZHOU ; Yi ZHENG ; Haiyan SHI ; Liang SHEN ; Longyu CHENG ; Dongyan WU ; Jun YU
Chinese Journal of Digestive Surgery 2022;21(S1):25-28
Immunotherapy combined with targeted therapy can benefit the survival of patients with unresectable hepatocellular carcinoma. Atezolizumab combined with bevacizumab has achieved remarkable efficacy in patients with advanced hepatocellular carcinoma, but the efficacy of conversion therapy in patients with unresectable hepatocellular carcinoma still needs more evidences. The authors report the clinical efficacy of a case of unresectable hepatocellular carcinoma with hepatitis B virus related liver cirrhosis who was treated with immunotherapy plus targeted therapy combined with local treatment. Results show a good effect in patient without tumor recurrence after postoperative 9 months.
Result Analysis
Print
Save
E-mail